Fool.com
The World's Greatest Investing Community
Results 31 - 40 of 1588 : Previous 1 2 3 4 5 6 7 8 9 Next
Pfizer's Generic Growth, With a Side of Sashimi
A move into Japan isn't a bad idea, but it isn't going to save the company either.
Drug Lowers Cholesterol; Stock Follows
ISIS has a hard time at AHA despite good efficacy data.
A new erectile-dysfunction drug shows promise.
Take a closer look at the insider action at MannKind.
Is the Small-Cap Rally Done for Good?
After roaring into the rally, small stocks are finally slowing down. Is the end near?
Bristol-Myers to Mead Johnson: It's time to walk on your own.
Small caps have the most growth potential.
Glaxo and Nabi team up for smokers who want to quit.
Why You Shouldn't Listen to Jim Cramer
Time and temperament are how you can beat the market.
Here's where the experts are placing their bets for next year.
Legal Information © 1995 - 2009 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK